News archive

Breast cancer drug could further reduce mortality

WEDNESDAY 14 FEBRUARY 2007

A study published online in the Lancet suggests breast cancer patients who switch drugs from tamoxifen to exemestane (Aromasin) are more likely to survive the disease. The study compared women who took tamoxifen for five years with women who switched to exemestane after two or three years of taking tamoxifen. According to the research, treating women with tamoxifen reduces the death rate by around 33 per cent while treating women with tamoxifen then switching to exemestane reduces the death rate by around 50 per cent.

If this treatment were rolled out across the UK, it could translate to around 1,300 fewer deaths each year. Lead researcher Professor Charles Coombes, director of the Cancer Research UK Laboratories and head of cancer medicine at Imperial College London, said: "Tamoxifen has already saved the lives of many breast cancer patients.

"Our latest research shows that we can build on that success by treating women first with tamoxifen then switching to the new drug, exemestane. "This is the first time any hormone treatment has been shown to reduce the death rate more than tamoxifen alone. Switching drugs also seems to avoid the side-effects of long-term tamoxifen therapy, such as cancer of the womb and deep vein thrombosis." Cancer Research UK's medical director Professor John Toy said: "These results are really very encouraging because they suggest that a sequence of tamoxifen and exemestane could help reduce breast cancer deaths. "We will continue to follow the results of this study to see how well the women fare in the long-term."

News provided by Adfero in collaboration with Cancer Research UK. Please note that all copy is © Adfero Ltd and does not reflect the views or opinions of Cancer Research UK unless explicitly stated.


* England on course to reduce cancer death rates by one fifth
* NICE recommends new lung cancer drug
* Teenagers not included in enough cancer trials
* Report prompts lower consumption of processed meats
* Study suggests some breast cancers may naturally regress
* Cancer Research UK welcomes new NHS drugs deal
* Information from brain tumour sacs may help to guide treatment
* Protein forces ovarian cancer cells to eat themselves
* Raising alcohol taxes shown to reduce deaths
* Scientists use new approach to hunt down cancer-causing genes
A - Z index A - Z index
Contact us Contact us
Donate now Donate now
Glossary Glossary
Print this page Print this page
AddThis Feed Button

Find out more
 
 
About this site   Accessibility   Donate now   Privacy   Site Map   Terms & Conditions   Top of page

Cancer Research UK is a registered charity No. 1089464.
Registered as a company limited by guarantee in England & Wales No. 4325234.
Registered address 61 Lincoln's Inn Fields, London, WC2A 3PX.